Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Cited by (1,003)

Items 801–900 of 1,003

1. Microenvironmental Clues for Glioma Immunotherapy
   Michael Platten, Katharina Ochs, Dieter Lemke, Christiane A. Opitz, Wolfgang Wick · 2014 · Current Neurology and Neuroscience Reports
2. Checkpoint immunotherapy in head and neck cancers
   Paul Zolkind, Ravindra Uppaluri · 2017 · Cancer and Metastasis Reviews
3. Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors
   Anthony R. Guastella, Sharon K. Michelhaugh, Neil V. Klinger, Hassan A. Fadel, Sam Kiousis, Rouba Ali‐Fehmi, William J. Kupsky, Csaba Juhász, Sandeep Mittal · 2018 · Journal of Neuro-Oncology
4. Current concepts of non-coding RNA regulation of immune checkpoints in cancer
   Maria Anna Smolle, Felix Prinz, George Adrian Calin, Martin Pichler · 2019 · Molecular Aspects of Medicine
5. Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance
   Jessica Godin-Ethier, Sandy Pelletier, Laïla‐Aïcha Hanafi, Philippe O. Gannon, Marie‐Andrée Forget, Jean‐Pierre Routy, Mohamed‐Rachid Boulassel, Urszula Krzemien, Simon Tanguay, Jean‐Baptiste Lattouf et al. · 2009 · The Journal of Immunology
6. Anti-Scarring Properties of Different Tryptophan Derivatives
   Malihe‐Sadat Poormasjedi‐Meibod, Ryan Hartwell, Ruhangiz Taghi Kilani, Aziz Ghahary · 2014 · PLoS ONE
7. Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
   Saman Maleki Vareki, Mateusz Rytelewski, René Figueredo, Di Chen, Peter J. Ferguson, Mark David Vincent, Wei‐Ping Min, Xiufen Zheng, James D. Koropatnick · 2014 · Oncotarget
8. Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors
   Subhankar Panda, Ashalata Roy, Suman Jyoti Deka, Vishal Trivedi, Debasis Manna · 2016 · ACS Medicinal Chemistry Letters
9. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
   Daniel Carvajal‐Hausdorf, Nikita Lavanya Mani, Vamsidhar Velcheti, Kurt Alex Schalper, David L. Rimm · 2017 · Journal for ImmunoTherapy of Cancer
10. Immunomodulatory Properties of Mesenchymal Stromal Cells: Still Unresolved “Yin and Yang”
    Alessandro Delli Poggi, Maria Raffaella Zocchi · 2018 · Current Stem Cell Research & Therapy
11. Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1
    Khoa Pham, Syun‐Ru Yeh · 2018 · Journal of the American Chemical Society
12. Indoleamine 2,3-Dioxygenase and Regulatory Function: Tryptophan Starvation and Beyond
    Ciriana Orabona, Ursula Grohmann · 2010 · Methods in molecular biology
13. Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase
    Shamaila Munir Ahmad, Stine Kiær Larsen, Trine Zeeberg Iversen, Marco Donia, Tobias Wirenfeldt Klausen, Inge Marie Svane, Per thor Straten, Mads Hald Andersen · 2012 · PLoS ONE
14. Association of Interferon‐gamma +874(T/A) Single Nucleotide Polymorphism with the Rate of Tryptophan Catabolism in Healthy Individuals
    Annika Raitala, M. Pertovaara, Jussi Karjalainen, Simo S. Oja, Mikko Hurme · 2005 · Scandinavian Journal of Immunology
15. Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer
    Bor‐Ching Sheu, Wen‐Hung Kuo, Ruey‐Jien Chen, Su‐Cheng Huang, King‐Jen Chang, Song‐Nan Chow · 2008 · The Breast
16. Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
    Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander M.M. Eggermont, Wolf H. Fridman, Jitka Palich Fucikova, Jérôme Galon, Radek Špíšek, Éric Tartour et al. · 2016 · OncoImmunology
17. Structure Inversion‐Bridged Sequential Amino Acid Metabolism Disturbance Potentiates Photodynamic‐Evoked Immunotherapy
    Lei Lei, Shengsheng Cai, Yan Zhang, Lianyi Yang, Jin Gen Deng, Heng Mei, Xuequan Zhang, Kun Zhang, Bin He, Jun Cao · 2022 · Advanced Functional Materials
18. The role of CD4+ T cells in tumor and chronic viral immune responses
    Luoyingzi Xie, Jingyi Fang, Juncheng Yu, Weinan Zhang, Zhiqiang He, Lilin Ye, Huaizhi Wang · 2023 · MedComm
19. An Inducible Mouse Model of Melanoma Expressing a Defined Tumor Antigen
    Ivo Johan Huijbers, Paul Krimpenfort, Patrick Chomez, Martin A. van der Valk, Ji‐Ying Song, Else Marit Inderberg, Anne‐Marie Schmitt‐Verhulst, Anton J. M. Berns, Benoit J. Van den Eynde · 2006 · Cancer Research
20. Innate immune sensing of cancer: clues from an identified role for type I IFNs
    Thomas F. Gajewski, Mercedes Beatriz Fuertes, Seng‐Ryong Woo · 2012 · Cancer Immunology Immunotherapy
21. microRNA-155, Induced by Interleukin-1ß, Represses the Expression of Microphthalmia-Associated Transcription Factor (MITF-M) in Melanoma Cells
    Nathalie Arts, Stefania Canè, Marc Hennequart, Juliette Lamy, Guido T. Bommer, Benoit J. Van den Eynde, Etienne De Plaen · 2015 · PLoS ONE
22. STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?
    Jr., Richard H. Bell · 2009 · CRC Press eBooks
23. l -Tryptophan–Kynurenine Pathway Metabolites Regulate Type I IFNs of Acute Viral Myocarditis in Mice
    Masato Hoshi, Keishi Matsumoto, Hiroyasu Ito, Hirofumi Ohtaki, Yuko Arioka, Yosuke Osawa, Yasuko Yamamoto, Hidetoshi Matsunami, Akira Hara, Mitsuru Seishima et al. · 2012 · The Journal of Immunology
24. Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways
    Siraj M. El Jamal, Erin B. Taylor, Zakaria Y. Abd Elmageed, Abdulhadi A. AlAmodi, Denis Selimović, Abdulaziz Alkhateeb, Matthias Hannig, Sofie-Yasmin Hassan, Simeon Santourlidis, Paul L. Friedlander et al. · 2016 · Cell Division
25. Immunosuppressive enzymes in the tumor microenvironment
    Valérie Molinier‐Frenkel, Flavia Castellano · 2017 · FEBS Letters
26. Impact of Tumor Microenvironment Composition on Therapeutic Responses and Clinical Outcomes in Cancer
    Fern M. Anari, Chethan Ramamurthy, Matthew R. Zibelman · 2018 · Future Oncology
27. PD ‐L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy
    Zachary Chinn, Mark H. Stoler, Anne M. Mills · 2018 · Histopathology
28. Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets
    Maria Sofia Basile, Emanuela Mazzon, Paolo Fagone, Antonio Longo, Andrea Russo, Matteo Fallico, Vincenza Maria Elena Bonfiglio, Ferdinando Nicoletti, Teresio Avitabile, Michele Reibaldi · 2019 · Frontiers in Oncology
29. Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
    Tianqi Wang, Yusuke Suita, Saradha Miriyala, Jordan Dean, Nikos Tapinos, Jie Shen · 2021 · Pharmaceutics
30. Constructing a fish metabolic network model
    Shuzhao Li, Alexander E. Pozhitkov, Rachel A Ryan, C. Steve Manning, Nancy J. Brown‐Peterson, Marius H. Brouwer · 2010 · Genome biology
31. Human tumor-specific T lymphocytes: does function matter more than number?
    Pierre G. Coulie, Thierry Connerotte · 2005 · Current Opinion in Immunology
32. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)
    Eduard Dolušić, Raphaël Frédérick · 2013 · Expert Opinion on Therapeutic Patents
33. Tumor Lactic Acidosis: Protecting Tumor by Inhibiting Cytotoxic Activity Through Motility Arrest and Bioenergetic Silencing
    Angelika J. Fischbeck, Svenja Rühland, Andreas W. Ettinger, Kerstin Paetzold, Ilias Masouris, Elfriede Noeßner, Anna N. Mendler · 2020 · Frontiers in Oncology
34. Strategies for Remodeling the Tumor Microenvironment Using Active Ingredients of Ginseng—A Promising Approach for Cancer Therapy
    Mo Li, Xin Wang, Ying Wang, Shunchao Bao, Qing Chang, Linlin Liu, Shuai Zhang, Liwei Sun · 2021 · Frontiers in Pharmacology
35. Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention
    Martin R. Jadus, Josephine Natividad, Anthony Mai, Yi Qin Ouyang, Nils W. G. Lambrecht, Sándor Szabó, Lisheng Ge, Neil T. Hoa, Maria G. Dacosta-Iyer · 2012 · Clinical and Developmental Immunology
36. Immunologic Approaches to Ovarian Cancer Treatment
    Paul J. Sabbatini, Kunle O. Odunsi · 2007 · Journal of Clinical Oncology
37. Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
    Vera V. Levina, Yunyun Su, Elieser Gorelik · 2012 · Clinical and Developmental Immunology
38. Targeting immune checkpoints in malignant glioma
    Xuhao Zhang, Shan Zhu, Tete Li, Yongjun Liu, Wei Chen, Jingtao Chen · 2016 · Oncotarget
39. An Expanding Role for Immunotherapy in Colorectal Cancer
    Katherine M. Bever, Dung Thi Le · 2017 · Journal of the National Comprehensive Cancer Network
40. Targeting TDO in cancer immunotherapy
    Chengpeng Yu, Yunlei Song, Zhengming Zhu, Bo Huang, Ying-Qun Xiao, Daya Luo · 2017 · Medical Oncology
41. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
    Michaela Poliaková Turan, Daniel M. Aebersold, Yitzhak Zimmer, Michaela Medová · 2018 · Molecular Cancer
42. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT
    Xueling Ou, Shaohui Cai, Peng Liu, Jun Zeng, Yuwen He, Xinyao Wu, Jun Du · 2007 · Journal of Cancer Research and Clinical Oncology
43. Molecular Basis for the Substrate Stereoselectivity in Tryptophan Dioxygenase
    Luciana Capece, Ariel Lewis-Ballester, Marcelo Adrian Marti, Dario Ariel Estrin, Syun‐Ru Yeh · 2011 · Biochemistry
44. Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy
    Huiru Zhang, Jigeng Fan, Deyang Kong, Yu Sun, Qi Zhang, Renshen Xiang, Shuaibing Lu, Wenjing Yang, Lin Feng, Haizeng Zhang · 2025 · Molecular Cancer
45. Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice
    Marcio O. Lasaro, Marina Sazanovich, Wynetta Giles‐Davis, Paulus Mrass, Ralph Milford Bunte, Duane A. Sewell, S. Farzana Hussain, Yang‐Xin Fu, Wolfgang Weninger, Yvonne Y.W. Paterson et al. · 2011 · Molecular Therapy
46. IDO Induces Expression of a Novel Tryptophan Transporter in Mouse and Human Tumor Cells
    Jonathan D. Silk, Samira Lakhal‐Littleton, Robert Laynes, Laura Vallius, Ioannis Karydis, Cornelius Marcea, C.A.R. Boyd, Vincenzo Cerundolo · 2011 · The Journal of Immunology
47. Activation of indoleamine 2,3-dioxygenase by LPS in a porcine model
    Elisa Wirthgen, Margret Tuchscherer, Winfried Otten, Grażyna Domańska, Karin Wollenhaupt, Armin Tuchscherer, Ellen Kanitz · 2013 · Innate Immunity
48. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors
    Eric D. Brooks, Jonathan E. Schoenhals, Chad Z. Tang, Goran Micevic, Daniel Richard Gomez, Joe Yujiao Chang, James William Welsh · 2016 · The Cancer Journal
49. Immunotherapy in ovarian cancer
    Venkatesh Krishnan, Jonathan S. Berek, Oliver Dorigo · 2016 · Current Problems in Cancer
50. Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer
    Ashley K. Volaric, Ryan D. Gentzler, Richard Delmar Hall, James Hunter Mehaffey, Edward B. Stelow, Timothy N. J. Bullock, Linda W. Martin, Anne M. Mills · 2018 · The American Journal of Surgical Pathology
51. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets
    Normann Steiner, Udo Müller, Roman Hájek, Sabina Ševčı́ková, Bojana Borjan, Karin Jöhrer, Georg Göbel, Andreas Pircher, Eberhard Gunsilius · 2018 · PLoS ONE
52. Tryptophan Metabolism Activates Aryl Hydrocarbon Receptor-Mediated Pathway To Promote HIV-1 Infection and Reactivation
    Yan-Heng Zhou, Li Xian Sun, Jun Chen, Weiwei Sun, Li Ma, Yang Han, Xia Jin, Qingxia Zhao, Taisheng Li, Hongzhou Lu et al. · 2019 · mBio
53. Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3
    Ri-Zhen Huang, Xiao-Teng Jing, Xiaochao Huang, Ying-Ming Pan, Yilin Fang, Gui-Bin Liang, Zhi‐Xin Liao, Heng‐Shan Wang, Zhen‐Feng Chen, Ye Zhang · 2020 · Journal of Medicinal Chemistry
54. Plasticity of NK cells in Cancer
    Dillon Corvino, Ananthi Kumar, Tobias Bald · 2022 · Frontiers in Immunology
55. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
    Xuerun Peng, Zhipeng Zhao, Liwen Liu, Lan Bai, Rongsheng Tong, Hao Yang, Lei Zhong · 2022 · Drug Design Development and Therapy
56. Immunotherapy resistance in solid tumors: mechanisms and potential solutions
    Daniel S. Lefler, Steven Anthony Manobianco, Babar Bashir · 2024 · Cancer Biology & Therapy
57. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia
    Ryoko Mabuchi, Takeshi Hara, Takuro Matsumoto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Masahito Shimizu et al. · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
58. Expression of Indoleamine 2,3-Dioxygenase in Human Corneal Cells as a Local Immunosuppressive Factor
    Yang‐Hwan Ryu, Jae-Chan Kim · 2007 · Investigative Ophthalmology & Visual Science
59. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance
    Gerald Willimsky, Karin Schmidt, Christoph Loddenkemper, Johanna Gellermann, Thomas J. F. Blankenstein · 2013 · Journal of Clinical Investigation
60. IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease
    Robert Sucher, Katharina Kurz, Günter Weiß, Raimund Margreiter, Dietmar Fuchs, Gerald Brandacher · 2010 · International Journal of Tryptophan Research
61. Substrate stereo‐specificity in tryptophan dioxygenase and indoleamine 2,3‐dioxygenase
    Luciana Capece, Mehrnoosh Arrar, Adrián E. Roitberg, Syun‐Ru Yeh, Marcelo Adrian Marti, Dario Ariel Estrin · 2010 · Proteins Structure Function and Bioinformatics
62. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis
    Roberto Pellicciari, Paride Liscio, Nicola Giacchè, Francesca Franco, Andrea Carotti, Janet Robertson, Lucia Cialabrini, Elena Katsyuba, Nadia Raffaelli, Johan H. Auwerx · 2018 · Journal of Medicinal Chemistry
63. Immunosuppression Routed Via the Kynurenine Pathway: A Biochemical and Pathophysiologic Approach
    Álvaro González, Nerea Varo, Estíbaliz Alegre, A. Ayechu Díaz, Ignacio Melero · 2008 · Advances in clinical chemistry
64. Roles of CD4+CD25high FOXP3+ Tregs in lymphomas and tumors are complex
    Xiaoyan Ke, Jing Wang, Lijuan Li, I-Ling Chen, Hong Wang, Xiaofeng Yang · 2008 · Frontiers in bioscience
65. Tumor stroma-associated antigens for anti-cancer immunotherapy
    Valeska Hofmeister, Claudia S. Vetter, David Schrama, Eva‐B. Bröcker, Jürgen Christian Becker · 2005 · Cancer Immunology Immunotherapy
66. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Félix Blanc‐Durand, Catherine Genestie, Elisa Yaniz‐Galende, Sébastien Gouy, Philippe Morice, Patricia Pautier, Amandine Maulard, Soizick Jeanne Lynette Mesnage, Audrey Le Formal, Chloé Brizais et al. · 2020 · Gynecologic Oncology
67. Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma
    Kirit Singh, Kelly M. Hotchkiss, Kisha K. Patel, Daniel S. Wilkinson, Aditya A Mohan, Sarah L. Cook, John Howard Sampson · 2021 · Cancers
68. The New Era of Cancer Immunotherapy
    Danny N. Khalil, Sadna Budhu, Billel Gasmi, Roberta Zappasodi, Daniel Hirschhorn-Cymerman, Tamar Plitt, Olivier De Henau, Dmitriy Zamarin, Rikke Holmgaard, Judith T. Murphy et al. · 2015 · Advances in cancer research
69. Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection
    Koyo Higashitani, Tatsuya Kanto, Shoko Kuroda, Sachiyo Yoshio, Tokuhiro Matsubara, Naruyasu Kakita, Tsugiko Oze, Masanori Miyazaki, Mitsuru Sakakibara, Naoki Hiramatsu et al. · 2012 · Journal of Gastroenterology
70. Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery
    Ausilia Sellitto, Gennaro Galizia, Umberto De Fanis, Eva Lieto, Anna Ginevra Immacolata Zamboli, Michele Orditura, Ferdinando De Vita, Riccardo Enzo Giunta, Giacomo Lucivero, Ciro Pasquale Romano · 2011 · Journal of Clinical Immunology
71. Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+T-Cell Functions in Esophageal Squamous Cell Carcinoma
    Ge Zhang, Wanli Liu, Lin Zhang, Junye Wang, Miao-huan Kuang, Peng Liu, Yuehao Lin, Shuqin Dai, Jun Du · 2011 · Clinical and Developmental Immunology
72. Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation
    Naoto Sato, Yasushi Saga, Hiroaki Mizukami, DONGDONG WANG, Suzuyo Takahashi, HIROAKI NONAKA, Hiroyuki Fujiwara, Yuji Takei, 静生 町田, Osamu Takikawa et al. · 2012 · Oncology Reports
73. New Cyclic Lipopeptides of the Iturin Class Produced by Saltern-Derived Bacillus sp. KCB14S006
    Sangkeun Son, Sung‐Kyun Ko, Mina Jang, Jong‐Won Kim, Gil Soo Kim, Jae Lee, Eun Jung Jeon, Yushi Futamura, In‐Ja Ryoo, Jung‐Sook Lee et al. · 2016 · Marine Drugs
74. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies
    Chuang Sun, Gianpietro Dotti, Barbara Savoldo · 2016 · Blood
75. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
    Yuka Kozuma, Kazuki Takada, Gouji Toyokawa, Kenichi Kohashi, Mototsugu Shimokawa, Fumihiko Hirai, Tetsuzo Tagawa, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara · 2018 · European Journal of Cancer
76. Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
    Geny Piro, Carmine Carbone, Luisa Carbognin, Sara Pilotto, Chiara Ciccarese, Roberto Iacovelli, Michèle Milella, Emilio Bria, Giampaolo Tortora · 2019 · Cancers
77. The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer
    Alexandra N. Giatromanolaki, Adrian Llewellyn Harris, Michael Ioannis Koukourakis · 2021 · Cancer & Metabolism
78. Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation
    Justin Paul Kline, Long Zhang, Lauren Battaglia, Kenneth Stuart Cohen, Thomas Frank Gajewski · 2012 · The Journal of Immunology
79. Cellular Immunotherapy of Cancer
    Fatma Visal Okur, Malcolm K. Brenner · 2010 · Methods in molecular biology
80. Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma
    Guanmin Jiang, Wanying Xie, Hongsheng Wang, Jun Du, WU Bai-ping, Wei Xu, Huifang Liu, Ping Xiao, Zhi-Gang Liu, Hongyan Li et al. · 2015 · Oncotarget
81. Challenges and future perspectives of T cell immunotherapy in cancer
    Maria Teresa P. de Aquino, Anshu Malhotra, Manoj Kumar Mishra, Anil Shanker · 2015 · Immunology Letters
82. Distinct metabolic differences between various human cancer and primary cells
    Katja Dettmer, Franziska C. Vogl, Axel P. Ritter, Wentao Zhu, Nadine Nürnberger, Marina P Kreutz, Peter Josef Oefner, Wolfram Gronwald, Eva Gottfried · 2013 · Electrophoresis
83. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease
    Marta Amaral, Tiago F. Outeiro, Nigel Shaun Scrutton, Flaviano Giorgini · 2013 · Journal of Molecular Medicine
84. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
    Gregory T. Wurz, Chiao-Jung Kao, Michael W. DeGregorio · 2015 · Therapeutic Advances in Medical Oncology
85. New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation
    Antonio Coluccia, Sara Passacantilli, Valeria Famiglini, Manuela Sabatino, Alexandros Patsilinakos, Rino Ragno, Carmela Mazzoccoli, Lorenza Sisinni, Alato Okuno, Osamu Takikawa et al. · 2016 · Journal of Medicinal Chemistry
86. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy
    Eric K. Ring, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman · 2016 · Clinical Cancer Research
87. Oncolytic viral therapy for pancreatic cancer
    Ahmad Khalil Rahal, Benjamin Musher · 2017 · Journal of Surgical Oncology
88. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
    Jan Budczies, Carsten Denkert, Balázs Győrffy, Peter Schirmacher, Albrecht Stenzinger · 2017 · BMC Medical Genomics
89. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
    Nausicaa Malissen, Jean‐Jacques Grob · 2018 · Drugs
90. Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy
    Haishi Qiao, Xingmei Chen, Enping Chen, Junmei Zhang, Dechun Huang, Danqi Yang, Youchao Ding, Hongliang Qian, Jan Feijén, Wei Chen · 2019 · Biomaterials Science
91. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy
    Jingjing Sun, Zhuoya Wan, Yichao Chen, Jieni Xu, Zhangyi Luo, Robert A. Parise, Dingwei Diao, Pengfei Ren, Jan Hendrik Beumer, Binfeng Lu et al. · 2020 · Acta Biomaterialia
92. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
    Martina Mandarano, Guido Bellezza, Maria Laura Belladonna, Jacopo Vannucci, Alessio Gili, Ivana Ferri, Chiara Lupi, Vienna Ludovini, Giulia Falabella, Giulio Metro et al. · 2020 · Frontiers in Immunology
93. The Coevolution of Placentation and Cancer
    Günter P. Wagner, Kshitiz Gupta, Anasuya Dighe, Andre Levchenko · 2021 · Annual Review of Animal Biosciences
94. Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression
    Mee Young Chang, Janette Boulden, Erika Sutanto‐Ward, James B. DuHadaway, Alejandro Peralta Soler, Alexander J. Muller, George C. Prendergast · 2007 · Cancer Research
95. Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase
    Christopher Austin, Jasminka Mizdrak, Azadeh Matin, Nick Sirijovski, Priambudi Kosim-Satyaputra, Robert D. Willows, Thomas H. Roberts, Roger J.W. Truscott, Galina Polekhina, Michael W. Parker et al. · 2004 · Protein Expression and Purification
96. Leukocyte Infiltration in Cancer Creates an Unfavorable Environment for Antitumor Immune Responses: A Novel Target for Therapeutic Intervention
    Vincenzo Bronte, Sara Cingarlini, Ilaria Marigo, Carmela De Santo, Giovanna Gallina, Luigi Dolcetti, Stefano Ugel, Elisa Peranzoni, Susanna Mandruzzato, Paola Zanovello · 2006 · Immunological Investigations
97. Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles
    Francesca Pistollato, Susanne Bremer‐Hoffmann, Giuseppe Basso, Sandra Sumalla Cano, Iñaki Elío, Manuel Masias Vergara, Francesca Giampieri, Maurizio Antonio Battino · 2015 · Targeted Oncology
98. Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
    Mads Hald Andersen · 2015 · JNCI Journal of the National Cancer Institute
99. Modification of the tumor microenvironment to enhance immunity
    Yu‐Pei Liao · 2007 · Frontiers in bioscience
100. HDACi: molecular mechanisms and therapeutic implications in the innate immune system
     Bandar A. Suliman, Dakang Xu, Bryan R.G. Williams · 2011 · Immunology and Cell Biology